A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Key Inclusion Criteria

• Signed informed consent must be obtained prior to participation in the study.
• Patients aged 18 years and older on the day of signing the informed consent.
• ITP cohort only: Confirmed diagnosis of primary ITP that has previously responded to corticosteroid treatment or IVIG treatment but the response was not sustained (response is defined as a platelet count ≥ 50 G/L).
• ITP cohort only: Received at least one prior treatment for ITP.
• ITP cohort only: Patients with a platelet count \< 100 G/L who are receiving a TPO-RA. Patients may already be receiving a TPO-RA or may start a TPO-RA at the time of screening. All patients should be on a stable dose of TPO-RA for at least 14 days prior to first dose of ianalumab. Note: during the screening period, a documented assessment of platelets \< 100 G/L is mandatory for enrollment. For patients who received rescue medication before screening, platelet count results obtained prior to the start of the rescue therapy should be used to assess eligibility if collected within 14 days prior to screening.
• ES cohort only: Patients with clinical diagnosis of primary ES with active thrombocytopenia (\< 100 G/L) with warm autoimmune hemolytic anemia (wAIHA) for whom a TPO-RA is appropriate per Investigator.
• ES cohort only: Inadequate response to or relapse after treatment with corticosteroid therapy.
• ES cohort only: Diagnosis confirmed by current or past positive direct antiglobulin test (DAT) (IgG+, with or without C3+) and evidence of hemolysis.
• ES cohort only: any supportive care treatment administered for wAIHA must be stable for at least 4 weeks prior to enrollment.

Key Exclusion Criteria

• Patients being treated with TPO-RA for > 6 months.
• Current life-threatening bleeding (related to thrombocytopenia).
• Prior splenectomy within 6 months of first administration of ianalumab.
• Patients with the following laboratory abnormalities:

• Neutrophils: \< 1000/mm3
• Serum creatinine > 1.5 × upper limit of normal (ULN)
• Aspartate aminotransferase (AST) > 3.0 × ULN
• Alanine aminotransferase (ALT) > 3.0 × ULN
• Immunoglobulin G (IgG) \< 5 g/L
• ITP cohort only: hemoglobin \< 10 g/L, total bilirubin > 1.5 × ULN
• Patients with significantly compromised liver disease (Child-Pugh 7 to 9) and decompensated liver disease (Child-Pugh 10 to 15).
• Treatment with a B-cell depleting therapy (e.g. rituximab or anti-B cell Activating Factor (e.g. belimumab) within 12 weeks prior to the first administration of ianalumab. Patients who are refractory to rituximab will be excluded from this trial, where refractory is defined as:

\~ Patients who have not achieved a response (defined as platelet count ≥ 30 G/L and at least doubling from baseline within 12 weeks in the absence of rescue therapy) following completion of a standard course of rituximab

• History of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes.
• Known history of primary or secondary immunodeficiency, or a positive human immunodeficiency virus (HIV) enzyme-linked immunosorbent assay (ELISA) and Western blot) test result.
• Patients exposed to more than 4 prior treatments for ITP.
• ITP cohort only: Diagnosis of secondary thrombocytopenia.
• ITP cohort: Use of immunosuppressant drugs other than corticosteroids or rituximab.
• ES cohort only: Diagnosis of secondary ES.
• ES cohort only: Life-threatening hemolysis.
• ES cohort only: patients with autoimmune hemolytic anemia other than wAIHA